J Appl Biotechnol Rep. 2025 December;12(4):1887-1888

doi 10.30491/jabr.2025.554511.1932

Journal of
Applied Biotechnology Reports

Commentary

Statistical Optimization of CYP124 Expression: A New Benchmark for Mycobacterial Cytochrome Engineering

Piruz Shadbash [1,2*], **Marzieh Bahari Babadi** [3]

[1] Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
[2] Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran
[3] Department of Biochemistry, Medical School, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Corresponding Author: Piruz Shadbash, PhD Candidate, Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Tel: +989032670910, E-mail: shadbashpiruz@gmail.com

Received October 20, 2025; **Accepted** October 25, 2025; **Online Published** December 30, 2025

Abstract
The study by Gunawan and colleagues (*J Appl Biotechnol Rep*. 2025;12(3)) introduces a statistically grounded optimization strategy for the heterologous expression of *Mycobacterium tuberculosis* CYP124 in *Escherichia coli* using the Box–Behnken Design (BBD). The research identifies the optimal combination of $FeCl_3$, δ-aminolevulinic acid (5-ALA), and IPTG for maximizing yield and purity of CYP124, a cytochrome P450 enzyme implicated in cholesterol metabolism and drug biotransformation. This commentary highlights the scientific significance, methodological robustness, and biotechnological implications of their findings, particularly in the context of tuberculosis (TB) drug discovery and enzyme engineering.

Keywords: Cytochrome P450, CYP124, *Mycobacterium tuberculosis*, Box-Behnken Design, Enzyme Engineering
Citation: Shadbash P, Bahari Babadi M. Statistical Optimization of CYP124 Expression: A New Benchmark for Mycobacterial Cytochrome Engineering. J Appl Biotechnol Rep. 2025;12(4):1887-1888. doi:10.30491/jabr.2025.554511.1932

Introduction

Cytochrome P450 enzymes (CYPs) play pivotal roles in the oxidative metabolism of endogenous and xenobiotic compounds.[1] In *Mycobacterium tuberculosis* (Mtb), several CYPs, including CYP124, are central to lipid catabolism and survival within macrophages.[2] CYP124 catalyzes ω-hydro xylation of methyl-branched lipids, sterols, and cholesterol derivatives pathways critical to the bacterium's persistence and pathogenicity.[3] Importantly, CYP124 can metabolize SQ109, an antitubercular drug candidate, thereby influencing therapeutic efficacy.[4] However, detailed functional and structural studies on CYP124 have been constrained by low heterologous expression yields. Gunawan et al. addressed this bottleneck through a rational statistical optimization approach, applying the Box–Behnken Design (BBD) under the Response Surface Methodology (RSM) framework to identify ideal culture conditions for CYP124 overproduction in *E. coli*.[1]

Significance of the Study

Gunawan et al. demonstrated a meticulous experimental design that bridges biostatistics and recombinant biotechnology. Their optimization of $FeCl_3$ (cofactor source), 5-ALA (heme precursor), and IPTG (inducer) concentrations led to a 1.4-fold increase in CYP124 yield (0.041 mg/L) relative to baseline conditions. Notably, 5-ALA emerged as the most influential variable, significantly improving both enzyme mass and purity (R/Z ratio). The interplay between IPTG and 5-ALA was also statistically significant, suggesting synergistic regulation between induction strength and heme biosynthesis. Conversely, excessive $FeCl_3$ concentrations negatively impacted yield, likely due to iron-induced stress or feedback inhibition an important reminder that more is not always better in protein expression systems. Furthermore, the authors validated enzyme functionality through farnesol-binding assays, revealing a dissociation constant (Kd) of 1.00 ± 0.14 μM, consistent with literature values for active CYP124. This demonstrates not only successful expression but also retention of catalytic competence.

Methodological Strengths

The study's methodological precision is noteworthy. By using Response Surface Methodology (RSM) rather than traditional one-variable-at-a-time approaches, the authors

achieved multi-factorial optimization with minimal experimental runs (15 total). This efficiency is especially valuable for resource-limited laboratories. The use of pCWORI vector and *E. coli* DH5α host system, alongside the inclusion of 5-ALA and Fe^{3+} ions for cofactor synthesis, reflects a well-informed design addressing both genetic and metabolic aspects of CYP expression. Moreover, the reported model error (0.03–1.44%) underscores the predictive accuracy of the statistical model, suggesting reproducibility and robustness.

Broader Biotechnological Implications

CYP124's ability to hydroxylate sterols and drug-like molecules highlights its dual relevance: as a drug target in tuberculosis therapy and as a biocatalyst in synthetic biology. By optimizing its recombinant expression, Gunawan et al. have laid groundwork for:

1. High-throughput screening of CYP124 inhibitors for antitubercular drug discovery.
2. Enzyme engineering and directed evolution studies to tailor CYP124's substrate specificity.
3. Biotransformation of complex lipids and terpenoids, potentially expanding green chemistry applications.

This work also contributes to the ongoing effort to express difficult Mtb enzymes in *E. coli*, an approach critical for studying pathogenic mechanisms and metabolic adaptations of *M. tuberculosis*.

Limitations and Future Directions

While the study provides a robust optimization framework, several aspects invite further exploration:

- **Scale-up validation:** Transitioning from flask to bioreactor conditions may alter oxygenation and cofactor dynamics, necessitating process re-optimization.
- **Comparative host systems:** Testing CYP124 expression in engineered *E. coli* strains with enhanced heme biosynthesis or chaperone co-expression could further improve yield.
- **Structural and kinetic assays:** Future work could explore crystal structures and turnover rates for different CYP124 substrates to deepen mechanistic insights.
- **Co-expression with redox partners:** Since CYP124 requires electron transfer proteins, incorporating its natural redox partners could improve catalytic efficiency.

Conclusion

Gunawan et al. have made a valuable contribution to microbial biotechnology by establishing a statistically validated and biochemically sound model for expressing functional CYP124 in *E. coli*. Their integration of Box–Behnken Design with biochemical validation exemplifies how statistical tools can accelerate enzyme engineering. By refining conditions for CYP124 production, this study facilitates both structural and pharmacological research on *M. tuberculosis* and provides a model for optimizing other challenging P450 systems.

Conflict of Interest Disclosures

The authors declare that they have no conflicts of interest.

References

1. Gunawan CM, Nurfadila MH, Utami RA, Pramastya H. Optimizing Heterologous Expression of CYP124 in *Escherichia coli* using Box-Behnken Design. J Appl Biotechnol Rep. 2025;12(3):1746-53. doi:10.30491/jabr.2024.470675.1766
2. Ortega Ugalde S, Boot M, Commandeur JN, Jennings P, Bitter W, Vos JC. Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in *Mycobacterium tuberculosis*: are they drug targets?. Appl Microbiol Biotechnol. 2019;103(9):3597-614. doi:10.1007/s00253-019-09697-z
3. Ghith A, Bruning JB, Bell SG. The catalytic activity and structure of the lipid metabolizing CYP124 cytochrome P450 enzyme from *Mycobacterium marinum*. Arch Biochem Biophys. 2023;737:109554. doi:10.1016/j.abb.2023.109554
4. Bukhdruker S, Varaksa T, Grabovec I, Marin E, Shabunya P, Kadukova M, et al. Hydroxylation of antitubercular drug candidate, SQ109, by mycobacterial cytochrome P450. Int J Mol Sci. 2020;21(20):7683. doi:10.3390/ijms21207683
5. Ghith A, Bruning JB, Bell SG. The catalytic activity and structure of the lipid metabolizing CYP124 cytochrome P450 enzyme from *Mycobacterium marinum*. Arch Biochem Biophys. 2023;737:109554. doi:10.1016/j.abb.2023.109554